Home/Pipeline/aNK / PD-L1 t-haNK Cell Therapies

aNK / PD-L1 t-haNK Cell Therapies

Various Solid Tumors

Phase 1/2Active

Key Facts

Indication

Various Solid Tumors

Phase

Phase 1/2

Status

Active

Company

ImmunityBio

About ImmunityBio

ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.

View full company profile

Therapeutic Areas

Bladder Cancer Non-Small Cell Lung Cancer Glioblastoma Lynch Syndrome Non-Hodgkin Lymphoma Ovarian Cancer HIV

Other Various Solid Tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Guardant Infinity Biomarker Discovery	Guardant Health	Development/Commercial	Active
Cytotoxic Oncology Generic	MSN Laboratories	Pre‑clinical	Active
APCEDEN®	APAC Biotech	Approved	Commercial
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
177Lu‑BetaBart (RV‑01)	AtomVie Global Radiopharma	Phase 1/2a	Active
BeiGene Oncology Portfolio	EVA Pharma	Phase 2/3	Active
Bevacizumab Biosimilar	Bio Usawa Biotechnology	Preclinical	Active